MY136065A - Prodrugs to nmda receptor ligands - Google Patents
Prodrugs to nmda receptor ligandsInfo
- Publication number
- MY136065A MY136065A MYPI20013876A MYPI20013876A MY136065A MY 136065 A MY136065 A MY 136065A MY PI20013876 A MYPI20013876 A MY PI20013876A MY PI20013876 A MYPI20013876 A MY PI20013876A MY 136065 A MY136065 A MY 136065A
- Authority
- MY
- Malaysia
- Prior art keywords
- prodrugs
- nmda receptor
- receptor ligands
- compounds
- lower alkyl
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003512 tertiary amines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
THE INVENTION RELATES TO COMPOUNDS OF THE GENERAL FORMULA WHEREIN R IS A)-C(O) (CH2)NC(O)OH, B) WHEREIN R1 IS –N(R2)(R3) AND R2/R3 ARE INDEPENDENTLY FROM EACH OTHER HYDROGEN OR LOWER ALKYL, OR IS A CYCLIC TERTIARY AMINE, OPTIONALLY SUBSTITUTED BY LOWER ALKYL,C) –P(O)(OH)2, OR IS D) –C(O)(CH2)NNHC(O)(CH2)NN(R2)(R3); AND N IS 1, 2, 3 OR 4; AND TO PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF. THESE COMPOUNDS MAY BE USED AS PRODRUGS FOR THE PARENT COMPOUND OF FORMULA WHICH ARE USEFUL IN THE TREATMENT OF NMDA RECEPTOR-RELATED DISEASES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00117918 | 2000-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY136065A true MY136065A (en) | 2008-08-29 |
Family
ID=8169594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20013876A MY136065A (en) | 2000-08-21 | 2001-08-17 | Prodrugs to nmda receptor ligands |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US6407235B1 (en) |
| EP (1) | EP1313703B1 (en) |
| JP (1) | JP4162991B2 (en) |
| KR (1) | KR100589991B1 (en) |
| CN (1) | CN1227230C (en) |
| AR (1) | AR030373A1 (en) |
| AT (1) | ATE386022T1 (en) |
| AU (2) | AU8589401A (en) |
| BR (1) | BR0113348A (en) |
| CA (1) | CA2419279C (en) |
| CY (1) | CY1107937T1 (en) |
| CZ (1) | CZ303319B6 (en) |
| DE (1) | DE60132782T2 (en) |
| DK (1) | DK1313703T3 (en) |
| EC (1) | ECSP034489A (en) |
| EG (1) | EG24293A (en) |
| ES (1) | ES2299508T3 (en) |
| HR (1) | HRP20030125B1 (en) |
| HU (1) | HU229802B1 (en) |
| IL (1) | IL154254A0 (en) |
| JO (1) | JO2289B1 (en) |
| MA (1) | MA26947A1 (en) |
| MX (1) | MXPA03001311A (en) |
| MY (1) | MY136065A (en) |
| NO (1) | NO324941B1 (en) |
| NZ (1) | NZ523990A (en) |
| PA (1) | PA8525601A1 (en) |
| PE (1) | PE20020291A1 (en) |
| PL (1) | PL204215B1 (en) |
| PT (1) | PT1313703E (en) |
| RS (1) | RS51467B (en) |
| RU (1) | RU2272027C2 (en) |
| SI (1) | SI1313703T1 (en) |
| WO (1) | WO2002016321A1 (en) |
| ZA (1) | ZA200300894B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1265864A1 (en) * | 2000-03-21 | 2002-12-18 | The Procter & Gamble Company | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors |
| US6713490B2 (en) | 2002-04-26 | 2004-03-30 | Pfizer, Inc. | 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists |
| CA2633010A1 (en) * | 2005-12-19 | 2007-06-28 | Methylgene Inc. | Histone deacetylase inhibitors for enhancing activity of antifungal agents |
| US8796330B2 (en) * | 2006-12-19 | 2014-08-05 | Methylgene Inc. | Inhibitors of histone deacetylase and prodrugs thereof |
| EP1973872A4 (en) | 2006-12-19 | 2012-05-09 | Methylgene Inc | Inhibitors of histone deacetylase and prodrugs thereof |
| PL4001272T3 (en) | 2013-11-05 | 2025-02-10 | Astrazeneca Ab | NMDA ANTAGONIST PRODRUGS |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1048247C (en) * | 1994-01-31 | 2000-01-12 | 美国辉瑞有限公司 | Neuroprotective chroman compounds |
| DE4410822A1 (en) | 1994-03-24 | 1995-09-28 | Schering Ag | New piperidine derivatives |
| TW340842B (en) * | 1995-08-24 | 1998-09-21 | Pfizer | Substituted benzylaminopiperidine compounds |
| TW498067B (en) | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
| TWI254043B (en) | 1999-06-08 | 2006-05-01 | Hoffmann La Roche | Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor |
-
2001
- 2001-08-16 PE PE2001000820A patent/PE20020291A1/en not_active Application Discontinuation
- 2001-08-16 PA PA20018525601A patent/PA8525601A1/en unknown
- 2001-08-16 US US09/931,431 patent/US6407235B1/en not_active Expired - Lifetime
- 2001-08-17 MY MYPI20013876A patent/MY136065A/en unknown
- 2001-08-17 AR ARP010103939A patent/AR030373A1/en active IP Right Grant
- 2001-08-19 JO JO2001136A patent/JO2289B1/en active
- 2001-08-20 ES ES01965201T patent/ES2299508T3/en not_active Expired - Lifetime
- 2001-08-20 AU AU8589401A patent/AU8589401A/en active Pending
- 2001-08-20 RS YUP-130/03A patent/RS51467B/en unknown
- 2001-08-20 EG EG20010906A patent/EG24293A/en active
- 2001-08-20 DK DK01965201T patent/DK1313703T3/en active
- 2001-08-20 RU RU2003107572/04A patent/RU2272027C2/en not_active IP Right Cessation
- 2001-08-20 MX MXPA03001311A patent/MXPA03001311A/en active IP Right Grant
- 2001-08-20 JP JP2002521197A patent/JP4162991B2/en not_active Expired - Fee Related
- 2001-08-20 CN CNB01814361XA patent/CN1227230C/en not_active Expired - Fee Related
- 2001-08-20 PT PT01965201T patent/PT1313703E/en unknown
- 2001-08-20 CA CA002419279A patent/CA2419279C/en not_active Expired - Fee Related
- 2001-08-20 HU HU0301548A patent/HU229802B1/en not_active IP Right Cessation
- 2001-08-20 EP EP01965201A patent/EP1313703B1/en not_active Expired - Lifetime
- 2001-08-20 CZ CZ20030492A patent/CZ303319B6/en not_active IP Right Cessation
- 2001-08-20 NZ NZ523990A patent/NZ523990A/en not_active IP Right Cessation
- 2001-08-20 SI SI200130812T patent/SI1313703T1/en unknown
- 2001-08-20 HR HR20030125A patent/HRP20030125B1/en not_active IP Right Cessation
- 2001-08-20 AU AU2001285894A patent/AU2001285894B2/en not_active Ceased
- 2001-08-20 AT AT01965201T patent/ATE386022T1/en active
- 2001-08-20 IL IL15425401A patent/IL154254A0/en not_active IP Right Cessation
- 2001-08-20 BR BR0113348-9A patent/BR0113348A/en not_active Application Discontinuation
- 2001-08-20 PL PL361387A patent/PL204215B1/en unknown
- 2001-08-20 DE DE60132782T patent/DE60132782T2/en not_active Expired - Lifetime
- 2001-08-20 KR KR1020037002485A patent/KR100589991B1/en not_active Expired - Fee Related
- 2001-08-20 WO PCT/EP2001/009561 patent/WO2002016321A1/en not_active Ceased
-
2003
- 2003-01-31 ZA ZA200300894A patent/ZA200300894B/en unknown
- 2003-02-19 NO NO20030781A patent/NO324941B1/en not_active IP Right Cessation
- 2003-02-20 EC EC2003004489A patent/ECSP034489A/en unknown
- 2003-02-21 MA MA27052A patent/MA26947A1/en unknown
-
2008
- 2008-05-08 CY CY20081100485T patent/CY1107937T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1485359T3 (en) | sodium | |
| IL150650A0 (en) | Piperidine derivatives and pharmaceutical compositions containing the same | |
| NZ511739A (en) | New esters derived from substituted phenyl-cyclohexyl compounds | |
| CY1107403T1 (en) | A METHOD FOR THE PREPARATION OF SUBSTANTOPRIL, THEIR analogues of these and their salts by the use of 2,5-intermediate compounds | |
| TW200602322A (en) | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | |
| ATE209645T1 (en) | NEW COMPOUND, METHOD FOR PRODUCTION THEREOF AND ANTITUMOR AGENTS | |
| NZ331060A (en) | Quinoxalinediones, preparation and pharmaceutical compositions thereof | |
| GB9408185D0 (en) | New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | |
| MY133445A (en) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivetives | |
| DE69828284D1 (en) | NAPHTHYRIDINE DERIVATIVES OR SALTS THEREOF | |
| IS2472B (en) | New tetrahydropyridine, production method and pharmaceutical compositions containing them | |
| MY136065A (en) | Prodrugs to nmda receptor ligands | |
| HRP20031055B1 (en) | NEW IMMUNOMODULATING COMPOUNDS | |
| IS7181A (en) | Aralkyl-tetrahydro-pyridine, their preparation and pharmaceutical compositions containing them | |
| HUT60710A (en) | Process for producing new substituted amine compounds | |
| EP1390343A4 (en) | Novel retinoid derivatives and methods for producing said compounds and an anti-cancer pharmaceutical composition comprising said compounds | |
| JO2433B1 (en) | Process for the preparation of heterocyclic indene analogs | |
| PL362126A1 (en) | New desloratadine salts, process for their synthesis and pharmaceutical compositions thereof | |
| EA200500032A1 (en) | DERIVATIVES OF ACYLOXYPYRROLIDINE AND THEIR APPLICATION AS V1B OR V1B AND V1A RECEPTORS LIGANDS | |
| EA200200682A1 (en) | NEW COMPOUNDS OF N-BENZYLPIPERASINE, METHOD OF THEIR RECEIVING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| IL150100A0 (en) | Pharmaceutical compositions containing fused cyclic compounds | |
| ATE488489T1 (en) | METHOD FOR REDUCTIVE DESHALOGENATION | |
| MXPA04002784A (en) | Pharmaceutically acceptable salts of 20(s)-camptothecins. | |
| DE69828037D1 (en) | Pyrroloindole derivatives and intermediates for their preparation |